Overview

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

Status:
Completed
Trial end date:
2017-09-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and clinical efficacy of ibrutinib in subjects with steroid dependent or refractory Chronic Graft Versus Host Disease.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Pharmacyclics LLC.